{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:36:22Z","timestamp":1792136182730,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.vaccine.2023.01.007","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T21:22:17Z","timestamp":1674163337000},"page":"1398-1407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country"],"prefix":"10.1016","volume":"41","author":[{"given":"Vianney","family":"Tricou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susannah","family":"Eyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahadev","family":"Ramjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6696-6826","authenticated-orcid":false,"given":"Paul","family":"Collini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1632-9268","authenticated-orcid":false,"given":"Zenaida","family":"Mojares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edde","family":"Loeliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Mandaric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9908-8852","authenticated-orcid":false,"given":"Martina","family":"Rauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manja","family":"Brose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0299-7783","authenticated-orcid":false,"given":"Nicolas","family":"Folschweiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.01.007_b0005","unstructured":"World Health Organization. Dengue and severe dengue. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue [accessed 17 March 2022]."},{"key":"10.1016\/j.vaccine.2023.01.007_b0010","unstructured":"World Health Organization. Dengue hemorrhagic fever: diagnosis, treatment, prevention and control. Available at: https:\/\/apps.who.int\/iris\/handle\/10665\/41988 [accessed 17 April 2022]."},{"key":"10.1016\/j.vaccine.2023.01.007_b0015","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro2460","article-title":"Dengue: a continuing global threat","volume":"8","author":"Guzman","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2023.01.007_b0020","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00705-013-1645-3","article-title":"Secondary infection as a risk factor for dengue hemorrhagic fever\/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection","volume":"158","author":"Guzman","year":"2013","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2023.01.007_b0025","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/14712598.2017.1356284","article-title":"Working towards dengue as a vaccine-preventable disease: challenges and opportunities","volume":"17","author":"Shrivastava","year":"2017","journal-title":"Exp Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2023.01.007_b0030","doi-asserted-by":"crossref","first-page":"11436","DOI":"10.1128\/JVI.77.21.11436-11447.2003","article-title":"Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development","volume":"77","author":"Huang","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.01.007_b0035","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","article-title":"Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever","volume":"29","author":"Osorio","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.007_b0040","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.007_b0045","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1016\/j.vaccine.2015.09.008","article-title":"Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1b randomized study","volume":"33","author":"Rupp","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.007_b0050","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jiv762","article-title":"Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study","volume":"213","author":"Sirivichayakul","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.007_b0055","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(17)30166-4","article-title":"Safety and immunogenicity of one versus two doses of Takeda\u2019s tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study","volume":"17","author":"S\u00e1ez-Llorens","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.007_b0060","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2\u201317 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study","volume":"18","author":"S\u00e1ez-Llorens","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.007_b0065","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2019.11.061","article-title":"Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial","volume":"38","author":"Tricou","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.007_b0070","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1080\/21645515.2020.1727697","article-title":"Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial","volume":"16","author":"Turner","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.01.007_b0075","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2\u201317 years: a randomised, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.01.007_b0080","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.01.007_b0085","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.01.007_b0090","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","article-title":"Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination","volume":"225","author":"L\u00f3pez-Medina","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.007_b0095","first-page":"ciab864","article-title":"Three years efficacy and safety of Takeda's dengue vaccine candidate (TAK-003)","author":"Rivera","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.007_b0100","unstructured":"WHO position paper on hepatitis A vaccines - June 2012. Wkly Epidemiol Rec 2012;87:261\u201376."},{"key":"10.1016\/j.vaccine.2023.01.007_b0105","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.01.007_b0110","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11908-018-0656-3","article-title":"Risk of Dengue in Travelers: Implications for Dengue Vaccination","volume":"20","author":"Wilder-Smith","year":"2018","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.vaccine.2023.01.007_b0115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.15585\/mmwr.mm6906a1","article-title":"Travel-Associated and Locally Acquired Dengue Cases - United States, 2010\u20132017","volume":"69","author":"Rivera","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.01.007_b0120","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.01.007_b0125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00063030-200317001-00005","article-title":"Rapid protection and vaccination against hepatitis A for travellers","volume":"17","author":"Connor","year":"2003","journal-title":"BioDrugs"},{"key":"10.1016\/j.vaccine.2023.01.007_b0130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.tmaid.2003.10.001","article-title":"Vaccination options for last-minute travellers in need of travel-related prophylaxis against hepatitis A and B and typhoid fever: a practical guide","volume":"1","author":"Zuckerman","year":"2003","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.007_b0135","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.vaccine.2011.11.051","article-title":"A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix in subjects aged 11\u201317 years: an open, randomised, controlled trial","volume":"30","author":"\u00d8stergaard","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.007_b0140","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/21645515.2015.1080395","article-title":"Concomitant use of VAQTA with PedvaxHIB and Infanrix in 12 to 17 month old children","volume":"12","author":"Petrecz","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.01.007_b0145","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4161\/hv.24873","article-title":"Concomitant administration of hepatitis A vaccine with measles\/mumps\/rubella\/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children","volume":"9","author":"Yetman","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.01.007_b0150","doi-asserted-by":"crossref","first-page":"e0003749","DOI":"10.1371\/journal.pntd.0003749","article-title":"The Complexity of a dengue vaccine: a review of the human antibody response","volume":"9","author":"Flipse","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.01.007_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41182-016-0004-y","article-title":"Human antibody response to dengue virus: implications for dengue vaccine design","volume":"44","author":"Moi","year":"2016","journal-title":"Trop Med Health"},{"key":"10.1016\/j.vaccine.2023.01.007_b0160","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2310\/7060.2000.00025","article-title":"Does the concurrent administration of an inactivated hepatitis A vaccine influence the immune response to other travelers vaccines?","volume":"7","author":"Bock","year":"2000","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2023.01.007_b0165","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/0264-410X(96)00059-X","article-title":"Interference assessment of yellow fever vaccine with the immune response to a single-dose inactivated hepatitis A vaccine (1440 EL.U.). A controlled study in adults","volume":"14","author":"Gil","year":"1996","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:22:23Z","timestamp":1759404143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0264410X23000075"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.007","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Takeda Vaccines. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}